Explore
Validate
Learn501908
antibody from BioLegend
Targeting: IL13
ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 501908 - Provider product page
- Provider
- BioLegend
- Proper citation
- BioLegend Cat#501908, RRID:AB_315203
- Product name
- APC anti-human IL-13
- Antibody type
- Monoclonal
- Antigen
- COS-expressed, recombinant human IL-13
- Description
- IL-13 is an immunoregulatory cytokine produced primarily by activated Th2 lymphocytes. IL-13 shares 30% amino acid sequence homology with IL-4 and demonstrates similar biological activities. The biological activities of IL-13 include: suppression of macrophage cytotoxic activity, upregulation of IL-1RA expression, and suppression of proinflammatory cytokine secretion. The JES10-5A2 antibody reacts with human interleukin-13 (IL-13). The JES10-5A2 antibody can neutralize the bioactivity of natural or recombinant IL-13.
- Reactivity
- Human
- Host
- Rat
- Conjugate
- Red dye
- Isotype
- IgG
- Vial size
- 50 µg
- Concentration
- 0.2 mg/ml
- Storage
- The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Submitted references Human TCR transgenic Bet v 1-specific Th1 cells suppress the effector function of Bet v 1-specific Th2 cells.
Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3.
Neunkirchner A, Leb-Reichl VM, Schmetterer KG, Mutschlechner S, Kueng HJ, Haiderer D, Schuch K, Wallner M, Jahn-Schmid B, Bohle B, Pickl WF
Journal of immunology (Baltimore, Md. : 1950) 2011 Oct 15;187(8):4077-87
Journal of immunology (Baltimore, Md. : 1950) 2011 Oct 15;187(8):4077-87
Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3.
Huber JP, Ramos HJ, Gill MA, Farrar JD
Journal of immunology (Baltimore, Md. : 1950) 2010 Jul 15;185(2):813-7
Journal of immunology (Baltimore, Md. : 1950) 2010 Jul 15;185(2):813-7
No comments: Submit comment
Supportive validation
- Submitted by
- BioLegend (provider)
- Main image
- Experimental details
- Enriched human CD4+ T cells were stimulated with PMA+ionomycin, then surface stained with CD4 PE/Cy5 and intracellular stained with APC rat IgG1,k isotype control (top) or APC JES10-5A2 (bottom)
- Conjugate
- Red dye
